TRACON Pharmaceuticals Performance
| TCONDelisted Stock | USD 1.60 0.55 52.38% |
The entity owns a Beta (Systematic Risk) of 2.24, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, TRACON Pharmaceuticals will likely underperform. TRACON Pharmaceuticals currently owns a risk of 0.0%. Please validate TRACON Pharmaceuticals treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if TRACON Pharmaceuticals will be following its current price history.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days TRACON Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, TRACON Pharmaceuticals is not utilizing all of its potentials. The newest stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 17.4 M |
TRACON |
TRACON Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 160.00 in TRACON Pharmaceuticals on August 29, 2024 and sell it today you would earn a total of 0.00 from holding TRACON Pharmaceuticals or generate 0.0% return on investment over 90 days. TRACON Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than TRACON, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
TRACON Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for TRACON Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as TRACON Pharmaceuticals, and traders can use it to determine the average amount a TRACON Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| TCON |
Based on monthly moving average TRACON Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of TRACON Pharmaceuticals by adding TRACON Pharmaceuticals to a well-diversified portfolio.
TRACON Pharmaceuticals Fundamentals Growth
TRACON Stock prices reflect investors' perceptions of the future prospects and financial health of TRACON Pharmaceuticals, and TRACON Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TRACON Stock performance.
| Return On Equity | -12.77 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | (32.12) % | ||||
| Current Valuation | (2.64 M) | ||||
| Shares Outstanding | 2.68 M | ||||
| Price To Earning | (1.51) X | ||||
| Price To Book | 11.83 X | ||||
| Price To Sales | 0.45 X | ||||
| Revenue | 12.04 M | ||||
| EBITDA | (6.88 M) | ||||
| Cash And Equivalents | 13.58 M | ||||
| Cash Per Share | 0.63 X | ||||
| Total Debt | 968 K | ||||
| Debt To Equity | 0.35 % | ||||
| Book Value Per Share | (0.66) X | ||||
| Cash Flow From Operations | 3.68 M | ||||
| Earnings Per Share | 106.40 X | ||||
| Total Asset | 10.11 M | ||||
| Retained Earnings | (240.5 M) | ||||
| Current Asset | 53.31 M | ||||
| Current Liabilities | 14.18 M | ||||
About TRACON Pharmaceuticals Performance
By examining TRACON Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into TRACON Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that TRACON Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California. Tracon Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.Things to note about TRACON Pharmaceuticals performance evaluation
Checking the ongoing alerts about TRACON Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for TRACON Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TRACON Pharmaceuticals is not yet fully synchronised with the market data | |
| TRACON Pharmaceuticals may become a speculative penny stock | |
| TRACON Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 12.04 M. Net Loss for the year was (3.59 M) with loss before overhead, payroll, taxes, and interest of (13.89 M). |
- Analyzing TRACON Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TRACON Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining TRACON Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TRACON Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of TRACON Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TRACON Pharmaceuticals' stock. These opinions can provide insight into TRACON Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in TRACON Stock
If you are still planning to invest in TRACON Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the TRACON Pharmaceuticals' history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |